NCT04601428 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Forner A, Gilabert M, Bruix J, Raoul JL
Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014 Sep;11(9):525-35. doi: 10.1038/nrclinonc.2014.122. Epub 2014 Aug 5.
Wang YH, Cheng TY, Chen TY, Chang KM, Chuang VP, Kao KJ
Plasmalemmal Vesicle Associated Protein (PLVAP) as a therapeutic target for treatment of hepatocellular carcinoma. BMC Cancer. 2014 Nov 6;14:815. doi: 10.1186/1471-2407-14-815.

CSR02-Fab-TF as Hepatic Intra-arterial Therapy in Intermediate Stage B or Limited Advanced Stage C Hepatocellular Carcinoma (HCC): Dose-Escalation Study to Assess Safety and Tolerability

Details for clinical trial NCT04601428

Clinical trial NCT04601428 - References